First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
PMID: 32843050
2020
Antimicrobial resistance and infection control
Conclusion: Detected RAMs were M41L, K70Q, V75I, Q151M, M184V and T215F for NRTI; K103N and V108I for NNRTI; and L10F, K20I, M36I, M46I, I47V, I54L, L63H, L76V, V82S and L89I for PI/r.
HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016.
Result: The most frequent mutations were L10I/V (32), A71I/T/V (28), and K20I/R (26), among which L10I/V and A71I/T/V are mutations that do not affect drug susceptibility and K20I/R were predicted to have potential resistance to NFV.
Discussion:
Discussion: In this study, among the PI-associated DR mutations detected, K20I/R and T74S were mainly found in CRF01_AE while A71I/T/V, Q58E, and V82I were frequently observed in CRF07_BC, indicating that the presence of different mutations may vary among different subtypes.
Polymorphisms and drug resistance analysis of HIV-1 isolates from patients on first line antiretroviral therapy (ART) in South-eastern Nigeria.
Discussion: I13V/A, K20I, M36I/L, R41K, H69K/R and L89M are the consensus mutations identified for subtypes G, UG and CRF02_AG while E35Q, R57K/G, C67E/S and V82I are the consensus mutations for G and UG in this study.
Discussion: In line with this, the only isolate with V82L mutation in this study, NG_IM.12_07, also harbours N88D mutation in addition to L10I and K20I mutations.
Discussion: Other mutations/polymorphisms that occurred at very high frequencies among patients in this
HIV-1 subtype diversity, drug resistance, and genetic transmission networks in men who have sex with men with virologic failure in antiretroviral therapy in Sichuan, China, 2011 to 2017.
Abstract: The most common drug resistance-associated mutations in protease inhibitors (PIs), NRTIs and NNRTIs were K20I/R, M184V/I and K103N/KN, respectively.
Result: The most common PI-related mutations were K20I/R (18/372, 4.84%) and V82I (13/372, 3.49%) (Table 3).
Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
Result: Most of these minority drug resistance mutations were detected in the 67 cART-experienced individuals, e.g., the HIV-1 genotype of the following patients consisted of a mixture of majority and minority drug resistance mutations: patient SG79 (PR V11I 99.9%, K20I 99.9%; RT E44D 1.3%, D67N 1.1%, L100I 1.7%, M184V 84.9%, M184I 14.8%, K219Q 2.1%, INT E157Q 99.8%), patient SG86 (RT M184V 99.8%, INT L74M 97.9%, L74I 1.9%, E92Q 86
Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaounde, Cameroon.
Method: Most of the subjects with major resistance mutation to NRTIs and/or NNRTIs harbored viruses that also had secondary resistance mutations to PIs: L10I, V11I, K20V, and K20I (Table 2).
Method: None of the 4 subjects on second line ART harbored viruses with major resistance mutation to PIs, but one of these subjects (NACMR039) harbored viruses with major resistance mutations to both NRTIs and NNRTIs, and a minor/secondary resistance mutation to PIs (K20I) (Table 2).
Table: K20I
Discussion: These subjects also
A decade of viral mutations and associated drug resistance in a population of HIV-1+ Puerto Ricans: 2002-2011.
Result: The 3 most prevalent HIV-1 resistance-associated mutations for PRO were L63P (73.9%), V77I (45.2%) and I13V (34.2%), whereas I50L, I50V and K20I were the least abundant mutations recorded during the 10-year period (Figs 2 and 4).
Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study.
HIV mutation literature information.
PMID: 
2020
Infectious disease reports
Browser Board
Co-occurred Entities
Filtrator
ViMRT